A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the
safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of
Durvalumab (MEDI4736) in combination with IPH2201 in Adult Subjects with selected advanced
solid tumors.